Can Sitagliptin reduce severe hypoglycemia risk in combination therapies by stabilizing glucose levels more effectively?
LifeLinkrLuminary
Can Sitagliptin reduce the risk of severe hypoglycemia in combination therapies?
Share
Sitagliptin, as a DPP-4 inhibitor, enhances insulin secretion and suppresses glucagon release, thus stabilizing blood glucose levels and potentially reducing the risk of severe hypoglycemia in combination therapies.